

1/13




Figure 1

2/13




Figure 2

3/13





Figure 3

4/13



SAC stimulation for 24 hours

Figure 4

5/13




Figure 5

6/13

Prolongation of graft survival induced by treatment with GCS




Figure 6

7/13

**Pretreatment of BALB/c splenic
cells with GCS reduces PHA-
stimulated proliferation**




Figure 7

8/13

**GCS-pretreated responder or
stimulator cells suppressed MLR
(BALB/c anti-C57/B6)**




Figure 8

9/13

GCS-pretreated DC reduced anti-allo T lymphocyte response




Figure 9

10/13

GCS affects monocytes
differentiate to dendritic cells




Figure 10

11/13

IDO-inhibitor (1-methyl-TRP) prevents GCS-induced suppression of PHA stimulation





Figure 11

12/13

IDO-inhibitor (1-methyl-TRP) prevents GCS-pretreated monocyte-induced, PHA stimulated T cell apoptosis




PHA stimulation (day 6)

Figure 12

13/13

IDO-inhibitor (1-methyl-TRP) prevents GCS-pretreated monocyte-induced, recall Ags stimulated T cell apoptosis



Recall antigen stimulation (day 6)

Figure 13